Advisor Group Holdings, Inc. Surface Oncology, Inc. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.61 - $1.03 $1,040 - $1,756	-1,705 Reduced 14.03%	10,450 $7,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $105 - $210	100 Added 0.83%	12,155 $13,000
Q2 2022 Aug 10, 2022	BUY	$1.42 - $3.15 $836 - $1,855	589 Added 5.14%	12,055 $20,000
Q1 2022 May 04, 2022	SELL	$2.65 - $5.08 $15,714 - $30,124	-5,930 Reduced 34.09%	11,466 $181,000
Q3 2021 Nov 05, 2021	BUY	$5.16 - $7.98 $8,054 - $12,456	1,561 Added 9.86%	17,396 $132,000
Q2 2021 Aug 02, 2021	BUY	$6.45 - $9.09 $52,890 - $74,538	8,200 Added 107.4%	15,835 $118,000
Q1 2021 May 13, 2021	BUY	$7.25 - $13.82 $33,444 - $63,751	4,613 Added 152.65%	7,635 $59,000
Q4 2020 Feb 10, 2021	BUY	$6.87 - $10.48 $5,839 - $8,908	850 Added 39.13%	3,022 $28,000
Q3 2020 Nov 12, 2020	BUY	$5.06 - $7.23 $2,530 - $3,615	500 Added 29.9%	2,172 $15,000
Q2 2020 Aug 14, 2020	BUY	$1.57 - $6.56 $2,625 - $10,968	1,672 New	1,672 $11,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.